273 related articles for article (PubMed ID: 16210038)
1. Idiopathic myelofibrosis.
Barosi G; Hoffman R
Semin Hematol; 2005 Oct; 42(4):248-58. PubMed ID: 16210038
[TBL] [Abstract][Full Text] [Related]
2. Idiopathic myelofibrosis: pathogenesis to treatment.
Reilly JT
Hematol Oncol; 2006 Jun; 24(2):56-63. PubMed ID: 16477581
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic stem cell transplantation as treatment for myelofibrosis.
Papageorgiou SG; Castleton A; Bloor A; Kottaridis PD
Bone Marrow Transplant; 2006 Dec; 38(11):721-7. PubMed ID: 17013423
[TBL] [Abstract][Full Text] [Related]
4. CD34+ progenitor cells in idiopathic (primary) myelofibrosis: a comparative quantification between spleen and bone marrow tissue.
Thiele J; Kvasnicka HM; Czieslick C
Ann Hematol; 2002 Feb; 81(2):86-9. PubMed ID: 11907788
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
Patriarca F; Bacigalupo A; Sperotto A; Isola M; Soldano F; Bruno B; van Lint MT; Iori AP; Santarone S; Porretto F; Pioltelli P; Visani G; Iacopino P; Fanin R; Bosi A;
Haematologica; 2008 Oct; 93(10):1514-22. PubMed ID: 18728030
[TBL] [Abstract][Full Text] [Related]
6. Differences in proportion and dynamics of recipient hematopoiesis following hematopoietic cell transplantation in CML and IMF.
Siebolts U; Thiele J; Zander T; Ditschkowski M; Beelen DW; Kröger N; Fehse B; Wickenhauser C
Oncol Rep; 2008 Jan; 19(1):287-92. PubMed ID: 18097609
[TBL] [Abstract][Full Text] [Related]
7. The syndrome of idiopathic myelofibrosis. A clinicopathologic review with emphasis on the prognostic variables predicting survival.
Varki A; Lottenberg R; Griffith R; Reinhard E
Medicine (Baltimore); 1983 Nov; 62(6):353-71. PubMed ID: 6633248
[TBL] [Abstract][Full Text] [Related]
8. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation.
Ciurea SO; Sadegi B; Wilbur A; Alagiozian-Angelova V; Gaitonde S; Dobogai LC; Akard LP; Hoffman R; Rondelli D
Br J Haematol; 2008 Apr; 141(1):80-3. PubMed ID: 18324970
[TBL] [Abstract][Full Text] [Related]
9. Transplant decision-making strategies in the myeloproliferative disorders.
Fruchtman SM
Semin Hematol; 2003 Jan; 40(1 Suppl 1):30-3. PubMed ID: 12682880
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
[TBL] [Abstract][Full Text] [Related]
11. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis.
Snyder DS; Palmer J; Stein AS; Pullarkat V; Sahebi F; Cohen S; Vora N; Gaal K; Nakamura R; Forman SJ
Biol Blood Marrow Transplant; 2006 Nov; 12(11):1161-8. PubMed ID: 17085309
[TBL] [Abstract][Full Text] [Related]
13. Rapid regression of bone marrow fibrosis after dose-reduced allogeneic stem cell transplantation in patients with primary myelofibrosis.
Kröger N; Thiele J; Zander A; Schwerdtfeger R; Kobbe G; Bornhäuser M; Bethge W; Schubert J; de Witte T; Kvasnicka HM;
Exp Hematol; 2007 Nov; 35(11):1719-22. PubMed ID: 17976523
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
15. Treatment approaches in myelofibrosis with myeloid metaplasia: the old and the new.
Tefferi A
Semin Hematol; 2003 Jan; 40(1 Suppl 1):18-21. PubMed ID: 12682877
[TBL] [Abstract][Full Text] [Related]
16. Biology and management of idiopathic myelofibrosis.
Smith BD; Moliterno AR
Curr Opin Oncol; 2001 Mar; 13(2):91-4. PubMed ID: 11224705
[TBL] [Abstract][Full Text] [Related]
17. Unrelated stem cell transplant for infantile idiopathic myelofibrosis.
Domm J; Calder C; Manes B; Crossno C; Correa H; Frangoul H
Pediatr Blood Cancer; 2009 Jul; 52(7):893-5. PubMed ID: 19241452
[TBL] [Abstract][Full Text] [Related]
18. Studies of the site and distribution of CD34+ cells in idiopathic myelofibrosis.
Ni H; Barosi G; Rondelli D; Hoffman R
Am J Clin Pathol; 2005 Jun; 123(6):833-9. PubMed ID: 15899773
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis.
Vazquez L; Caballero D; Cañizo CD; Lopez C; Hernandez R; Gonzalez I; Flores T; San Miguel JF
Bone Marrow Transplant; 2000 Jan; 25(2):217-8. PubMed ID: 10673685
[TBL] [Abstract][Full Text] [Related]
20. Chronic idiopathic myelofibrosis: prognostic impact of myelofibrosis and clinical parameters on event-free survival in 122 patients who presented in prefibrotic and fibrotic stages. A retrospective study identifying subgroups of different prognoses by using the RECPAM method.
Kreft A; Weiss M; Wiese B; Choritz H; Buhr T; Büsche G; Georgii A
Ann Hematol; 2003 Oct; 82(10):605-11. PubMed ID: 14564478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
